Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Raised to Strong-Buy at Hsbc Global Res

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by Hsbc Global Res from a “hold” rating to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

BAYRY has been the subject of several other reports. The Goldman Sachs Group upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Thursday, June 5th. Kepler Capital Markets upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, Wall Street Zen upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Friday, June 6th. One investment analyst has rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Bayer Aktiengesellschaft currently has an average rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

OTCMKTS:BAYRY opened at $8.03 on Wednesday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.81 and a current ratio of 1.32. The stock’s 50-day simple moving average is $6.62 and its 200 day simple moving average is $5.93. The company has a market cap of $31.56 billion, a P/E ratio of -30.88 and a beta of 0.85. Bayer Aktiengesellschaft has a 52-week low of $4.79 and a 52-week high of $8.58.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Tuesday, May 13th. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. Bayer Aktiengesellschaft had a positive return on equity of 16.90% and a negative net margin of 2.02%. The business had revenue of $15.27 billion for the quarter, compared to the consensus estimate of $13.39 billion. As a group, sell-side analysts forecast that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.